MXB 005
Alternative Names: MXB-005; MXB-5Latest Information Update: 28 May 2025
At a glance
- Originator Maxwell Biosciences
- Class Antimicrobial cationic peptides; Antivirals; Peptoids; Small molecules
- Mechanism of Action Viral envelope protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Herpes labialis
Most Recent Events
- 28 May 2025 No recent reports of development identified for preclinical development in Herpes labialis in USA (Topical)
- 10 Apr 2021 Maxwell Biosciences plans a clinical trial for Herpes labialis (Recurrent) in USA (Topical) (Maxwell Biosciences pipeline, April 2021)
- 08 Apr 2021 Maxwell Biosciences has patent protection for composition of matter portfolio for its anti-infectives program (Maxwell Biosciences pipeline, April 2021)